Find trials
Search tips

Studying Biomarkers In Diagnosing Cervical Lesions In Patients With Abnormal Cervical Cells

Overview

About this study

This clinical trial is studying biomarkers in diagnosing cervical lesions in patients with abnormal cervical cells. Studying biomarkers in abnormal cervical cells may improve the ability to find cervical lesions and plan effective treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Cytologically confirmed atypical glandular cells (AGC), including any of the following types:
    • AGC of unclear cell origin
    • Atypical endocervical cells (AEC)
    • Atypical endometrial cells (AEmC)
  • Must be able to wait ≥ 1 week after initial AGC diagnosis before beginning intervention
  • No history of endometrial hyperplasia or cancer of the endometrium, vagina, or cervix
  • No known HIV positivity
  • Not pregnant
  • Negative pregnancy test
  • No prior hysterectomy
  • No prior or concurrent radiotherapy or chemotherapy for vaginal or cervical cancer

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Andrea Wahner Hendrickson, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20116123

Mayo Clinic Footer